Sun Pharma unveils Leqselvi in US for severe Alopecia Areata Ruchika Sharma14 July 2025 11:56 AMMumbai: Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S. following...
Sun Pharma, Incyte settle dispute over LEQSELVI Ruchika Sharma14 July 2025 11:00 AMMumbai: Sun Pharmaceutical Industries Limited has announced that Sun and Incyte Corporation have entered into a settlement and license agreement...
Court Removes Injunction on Sun Pharma's LEQSELVI Launch in US Farhat Nasim10 April 2025 12:35 PMDelhi: In a major relief to Sun Pharmaceutical Industries Ltd, the U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction...
Sun Pharma presents Leqselvi data highlighting clinical efficacy, durability for Alopecia Areata treatment at 2024 Fall Clinical Dermatology Conference Ruchika Sharma28 Oct 2024 6:00 AMMumbai: Sun Pharmaceutical Industries Limited has presented new data highlighting the clinical efficacy and safety of LEQSELVI (deuruxolitinib) 8...
Twice-Daily Deuruxolitinib Significantly Improves Alopecia Areata Over 24 Weeks: Study Dr Riya Dave11 Oct 2024 2:30 PMResearchers found that twice-daily deuruxolitinib (Leqselvi), at an 8 mg dose, significantly improved hair satisfaction of patients with severe...
Sun Pharma presents new clinical efficacy, safety data in severe dermatological conditions at 2024 EADV Congress Ruchika Sharma27 Sept 2024 10:21 AMMumbai: Sun Pharmaceutical Industries Limited has announced that it will present abstracts across its dermatology portfolio at the 33rd European...
FDA approves oral deuruxolitinib for severe alopecia areata Dr. Kamal Kant Kohli29 July 2024 4:15 PMThe US Food and Drug Administration (FDA) has approved oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2 deuruxolitinib (Lesqselvi) 8 mg...
Sun Pharma gets USFDA nod for alopecia areata drug Leqselvi Ruchika Sharma26 July 2024 6:04 AMLEQSELVI is a new, twice daily oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2.
Sun Pharma arm signs licensing agreement with Aclaris Therapeutics Ruchika Sharma6 Dec 2023 7:00 AMThe agreement includes an upfront payment of USD 15 million, regulatory and commercial milestones, and royalties.
USFDA accepts Sun Pharma NDA for alopecia areata drug Deuruxolitinib Ruchika Sharma6 Oct 2023 8:22 AMMumbai: Sun Pharmaceutical Industries Ltd has announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application...
Sun Pharma reports consolidated net profit of Rs 1984 crore in Q4 Ruchika Sharma27 May 2023 8:00 AM"Several of our businesses, including specialty, India and emerging markets have continued to progress well," Sun Pharma Managing Director Dilip...
USFDA halts Sun Pharma trials on dermatological drug Deuruxolitinib Ruchika Sharma2 May 2023 9:16 AMThe company said it would work closely with the FDA to address the agency's concerns, which the drugmaker expected to be communicated within the next...
